Ord Minnett’s Post

YPOG advised lead investor Vesalius Biocapital IV on the Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund, and HTGF | High-Tech Gründerfonds also participated in the investment.   The new funding will support the Phases Ib/ IIa clinical trial focused on improving liver healing and preventing liver failure.   Congratulations to our client Vesalius and all parties involved!   The YPOG team was led by Martin Schaper and included Dr. Lutz Schreiber, Benjamin Müller, Matthias Treude as well as Cyra Dittberner.   ➡ Link to the press release in the comments below.   #YPOG #PartnersOfGamechangers #VentureCapital #Growth #Funds #Transactions

Following our recent acquisition of Reach Separations, here’s what Peter Ridgway, Business Development Director at Reach Separations, had to say: "Becoming part of the CatSci Ltd Group will enhance and strengthen Reach Separations’ ability to deliver excellence in chromatography. Integrating our technologies and expertise across the discovery and development landscape will provide a one-stop-shop for analysis and purification, giving the client a variety of options to progress the journey of their asset. As one of the founders of Reach Separations, I am delighted to join forces with CatSci to deliver strong growth and expand separation science into new marketplaces." This strategic acquisition marks a significant milestone for CatSci and enhances our ability to deliver programmes where rapid purification by chromatography is often essential to expediting clinical development. Together with Reach, we will drive forward our shared mission to deliver excellence in medicines development.   Learn more about how this acquisition will solve our customers' separation science challenges: https://lnkd.in/ebprErGt #ExcellenceInMedicinesDevelopment #ProudToBeCatSci #DrugDevelopment #MedicinesDevelopment

Breaking news! James Hussey, CEO at Seneca Therapeutics, Inc. will join The Keiretsu Family Office Forum as a part of the Family Office Investment Outlook Panel. Register now to hear his thoughts about the current landscape of family office investment: https://lnkd.in/dynZpRff #InvestorCapitalExpo #FamilyOfficeForum #AngelEcosystem #InvestorCapitalExpo2024 #AngelInvesting #AngelCommunity

Meysan advised Sanam Innovation Holding Company (SIHC) and Arzan Financial Group For Financing & Investment K.P.S.C. as buyers in their acquisition of 75% of NATMED. The transaction is valued at approximately $33 million. The Meysan team was led by partner Abdulwahab Sadeq (pictured). Further, it was supported by senior associate Adel Al Asousi and associate Nour Berbari. Read the full article >> https://lnkd.in/dXcr2dEZ #LegalcommunityMENA #legaladvisor #acquisition

Oculis rings the Nasdaq Iceland opening bell! 🇮🇸 🔔   Today, Oculis became dual-listed on the Nasdaq Iceland Main Market, complementing its existing listing on the Nasdaq Global Market in the U.S. (Nasdaq: OCS).   Preceding the Iceland listing, Oculis successfully closed an oversubscribed equity financing round of $59 million. This funding round included new Icelandic institutional investors as well as participation from existing investors, thereby extending the cash runway until the second half of 2026 and remain on track for significant catalysts in the innovative pipeline.   Later this quarter, we anticipate the readout from Phase 2b RELIEF trial of OCS-02 in Dry Eyes Disease (DED). 👁   Read the press release here 👉 https://lnkd.in/eztX8hjE #Nasdaq #eyehealth #biotech #ophthalmology Riad, Páll, Thorsteinn, Einar, Sylvia, Gudrun Marta, Gudrun Bachmann, Arni, Jón, Rut.

Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved ·      Funds deposited for cash quota and to cover legal costs ·      European Investment Bank (EIB) agrees to standstill declaration ·      Implementation of the restructuring plan and the Company's sustainable continued existence are to be secured by the sale of the Carragelose business “We have experienced very challenging months. Despite the difficulties, we have been able to develop a restructuring plan that provides an acceptable solution for our creditors and ensures the stable financing of the Company. The two capital increases that have been carried out are also significant for securing our cash situation. We are grateful for the continued support and trust placed in us,” says Andreas Grassauer, CEO of Marinomed. The full press release is available here: https://lnkd.in/dWdc5Qux #oceanofideas

Learn how logistics can save lives in this episode of Logistics With Purpose®! Enrique Alvarez and Wade Stiles are joined by John Bruens, founder and CEO of Global Transplant Solutions (GTS). John shares his journey from professional soccer player to biopharma entrepreneur, and how GTS is revolutionizing organ preservation logistics. Discover how their innovative cold chain solutions ensure that no one dies waiting for an organ and how GTS's mission to save lives is reflected in every employee being a registered organ donor. 🎧 Listen Now: https://bit.ly/40AbKza #LogisticsWithPurpose #HealthcareInnovation #OrganDonation #ColdChainLogistics #Biopharma #SupplyChainManagement Vector Global Logistics

📹 In the first part of her video interview, Delphine Perridy Boile, chief commercial officer, Envirotainer, describes the progression of expectations when it comes to the sector, specifically as it relates to new #drugdevelopment

#Cannabis investors looking for MSOs should look at these two

Our Chief Commercial Officer, Delphine Perridy Boile, recently spoke with Pharmaceutical Commerce Magazine about the rapid evolution in pharma driven by unserved patient needs, new technologies, and AI in drug discovery. She highlights the importance of precise temperature control and customized logistics, especially for biologics and personalized medicines, as the industry adapts to bring innovative treatments to patients faster. Read the full interview below for more insights on the future of pharma cold chain and sustainability. #Envirotainer #PharmaInnovation #ColdChainLogistics